CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non–small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103+ TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8+CD103+ TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1–PD-L1 interaction. These findings emphasize the role of CD8+CD103+ tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti–PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further research revealed that the presence of CD103+CD8+ TILs is a positive prognostic marker in several cancers [269-272].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [270]
In the citing paper
“Previous studies demonstrated that enhanced CD8+CD103+ TRM TILs correlate with improved survival in patients with early stage NSCLC18 and with other types of cancer19.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [18]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 5×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundInfluentialFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“Among these inhibitory receptors, CTLA-4, PD-1, and Tim3 appeared to be associated with T cell exhaustion in chronic viral infections (35–38) and tumor progression (39).”
BackgroundPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111 · cited 1×
“In the latter and present studies, CD103 T cells expressed high levels of PD-1, which has been defined as a biomarker of tumor-specific T cells (33).”
BackgroundSkin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
BackgroundHenderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., Pellicoro, A., Raschperger, E., Betsholtz, C., Ruminski, P. G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3282 · Cited by 866 · cited 1×
“understood, but it may reflect interpatient variations in the intratumoral level of TGF-b1 or factors involved in its activation, such as aV integrins (30, 31), the number of tumor Ag-specific T cell precursors, or both.”
BackgroundSkon, C. N., Lee, J.-Y., Anderson, K. G., Masopust, D., Hogquist, K. A., & Jameson, S. C. (2013) · Nature Immunology · doi:10.1038/ni.2745 · Cited by 817 · cited 1×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundSphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
Cyster, J. G., & Schwab, S. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075011 · Cited by 815 · cited 1×
“Although the natural ligand for CD69 has not been clearly defined, evidence for an interaction of CD69 with S1P1, a receptor for sphingosine 1-phosphate that mediates the egress of T cells from lymphoid organs (26), has”
BackgroundJones, R. B., Ndhlovu, L. C., Barbour, J. D., Sheth, P. M., Jha, A. R., Long, B. R., Wong, J. C., Satkunarajah, M., Schweneker, M., Chapman, J. M., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081398 · Cited by 753 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundMackay, L. K., Stock, A. T., Ma, J. Z., Jones, C. M., Kent, S. J., Mueller, S. N., Heath, W. R., Carbone, F. R., & Gebhardt, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202288109 · Cited by 635 · cited 1×
“(24), and provide early responses to viral reinfection (25).”
BackgroundDynamic T cell migration program provides resident memory within intestinal epithelium
Masopust, D., Choo, D., Vezys, V., Wherry, E. J., Duraiswamy, J., Akondy, R., Wang, J., Casey, K. A., Barber, D. L., Kawamura, K. S., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090858 · Cited by 628 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
BackgroundSelective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade
Blackburn, S. D., Shin, H., Freeman, G. J., & Wherry, E. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801497105 · Cited by 579
Wakim, L. M., Woodward-Davis, A., & Bevan, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010201107 · Cited by 575 · cited 2×
“Consistently, CD103 was maintained on vesicular stomatitis virus-specific CD8 T cells only as long as the Ag was present (21).”
BackgroundKaufmann, D. E., Kavanagh, D. G., Pereyra, F., Zaunders, J. J., Mackey, E. W., Miura, T., Palmer, S., Brockman, M., Rathod, A., Piechocka-Trocha, A., et al. (2007) · Nature Immunology · doi:10.1038/ni1515 · Cited by 524
Essential role for CD103 in the T cell–mediated regulation of experimental colitis
Annacker, O., Coombes, J. L., Malmstrom, V., Uhlig, H. H., Bourne, T., Johansson-Lindbom, B., Agace, W. W., Parker, C. M., & Powrie, F. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20040662 · Cited by 483
Sung, S.-S. J., Fu, S. M., Rose, C. E., Gaskin, F., Ju, S.-T., & Beaty, S. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.4.2161 · Cited by 476
Webb, J. R., Milne, K., Watson, P., deLeeuw, R. J., & Nelson, B. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1877 · Cited by 434
Zhang, N., & Bevan, M. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.08.019 · Cited by 433 · cited 2×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
BackgroundReinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
Freeman, G. J., Wherry, E. J., Ahmed, R., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061800 · Cited by 399
The Molecular Signature of Tissue Resident Memory CD8 T Cells Isolated from the Brain
Wakim, L. M., Woodward-Davis, A., Liu, R., Hu, Y., Villadangos, J., Smyth, G., & Bevan, M. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201305 · Cited by 363 · cited 4×
“Our results revealed that CD103+ TIL display a transcriptomic signature characteristic of TRM cells, with downregulation of S1P1 and upregulation of RGS1 and ICOS as well as genes encoding PD-1 and Tim-3, along with Bag-3 and transcription factors EGR1 and Nr4a2 (18, 19).”
BackgroundInfluentialEl-Asady, R., Yuan, R., Liu, K., Wang, D., Gress, R. E., Lucas, P. J., Drachenberg, C. B., & Hadley, G. A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041044 · Cited by 271
Floc'h, A. L., Jalil, A., Vergnon, I., Chansac, B. L. M., Lazar, V., Bismuth, G., Chouaib, S., & Mami-Chouaib, F. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061524 · Cited by 269 · cited 5×
“The cytotoxic activity of TIL was measured by a conventional (51)Crrelease assay (3).”
BackgroundMethodInfluentialSelf-citationA new surface antigen on intraepithelial lymphocytes in the intestine
Kilshaw, P. J., & Murant, S. J. (1990) · European Journal of Immunology · doi:10.1002/eji.1830201008 · Cited by 214 · cited 1×
“CD103 is expressed at high levels by mucosal CD8 T lymphocytes, in particular intestinal intraepithelial lymphocytes (4), but it is also found on mucosal mast cells and dendritic cells (5), CD4 and CD8 regulatory T cells (6), and on a large proportion of CD8 T cells infiltrating epithelial tumors, including pancreatic…”
BackgroundFranciszkiewicz, K., Le Floc'h, A., Boutet, M., Vergnon, I., Schmitt, A., & Mami-Chouaib, F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2569 · Cited by 189 · cited 1×
“CD103 ligation to E-cadherin not only promotes Ag recognition by favoring T cell adhesion to specific tumor cells (12), but it also induces costimulation in activated CTL by triggering signals that”
BackgroundSelf-citationPiet, B., de Bree, G. J., Smids-Dierdorp, B. S., van der Loos, C. M., Remmerswaal, E. B. M., von der Thüsen, J. H., van Haarst, J. M. W., Eerenberg, J. P., ten Brinke, A., van der Bij, W., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44675 · Cited by 183 · cited 3×
“but not EBV- and CMV-specific T lymphocytes, express the integrin, further emphasizing that a sufficient Ag amount is needed to maintain CD103 expression (24).”
BackgroundAnikeeva, N., Somersalo, K., Sims, T. N., Thomas, V. K., Dustin, M. L., & Sykulev, Y. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502467102 · Cited by 179
Mulé, J. J., Custer, M. C., Averbook, B. J., Yang, J. C.-H., Weber, J. S., Goeddel, D. V., Rosenberg, S. A., & Schall, T. J. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.13-1545 · Cited by 143 · cited 1×
“involved in regulating antitumor immune responses (45).”
CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner
Mañes, S., Mira, E., Colomer, R., Montero, S., Real, L. M., Gómez‐Moutón, C., Jiménez-Baranda, S., Garzón, A., Lacalle, R. A., Harshman, K., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030580 · Cited by 140 · cited 1×
“tration, poor prognosis (48, 49), and reduced efficacy of cancer immunotherapy (50).”
BackgroundThe secretory synapse: the secrets of a serial killer
Bossi, G., Trambas, C., Booth, S., Clark, R., Stinchcombe, J. C., & Griffiths, G. M. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18913.x · Cited by 122 · cited 1×
“somes containing perforin and granzymes, into the specific target leading to cell death (1).”
BackgroundCD103 Expression Is Required for Destruction of Pancreatic Islet Allografts by CD8+ T Cells
Feng, Y., Wang, D., Yuan, R., Parker, C. M., Färber, D. L., & Hadley, G. A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020178 · Cited by 110
Franciszkiewicz, K., Floc’h, A. L., Jalil, A., Vigant, F., Robert, T., Vergnon, I., Mackiewicz, A. A., Benihoud, K., Validire, P., Chouaı̈b, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3571 · Cited by 104 · cited 7×
“specific cancer cells contributes, at least in part, to T cell retention within the tumor by inhibiting lymphocyte responsiveness to CCL5 (29).”
BackgroundInfluentialSelf-citationFloc’h, A. L., Jalil, A., Franciszkiewicz, K., Validire, P., Vergnon, I., & Mami‐Chouaib, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2457 · Cited by 104 · cited 1×
“cooperate with TCR-mediated signaling (13).”
Self-citationIncorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC
Champiat, S., Ileana, E. E., Giaccone, G., Besse, B., Mountzios, G., Eggermont, A. M. M., & Soria, J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000074 · Cited by 103 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundSelf-citationGuarding the perimeter: protection of the mucosa by tissue-resident memory T cells
Cauley, L. S., & Lefrançois, L. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.96 · Cited by 102 · cited 1×
“been suggested to also play a role in retention of TRM T cells by modulating their capacity to exit nonlymphoid tissues (27).”
BackgroundUgurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0407-z · Cited by 88 · cited 1×
“tration, poor prognosis (48, 49), and reduced efficacy of cancer immunotherapy (50).”
BackgroundSmad and NFAT Pathways Cooperate To Induce CD103 Expression in Human CD8 T Lymphocytes
Mokrani, M., Klibi, J., Bluteau, D., Bismuth, G., & Mami‐Chouaib, F. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302192 · Cited by 86
Self-citationQuinn, E., Hawkins, N. J., Yip, Y. L. K., Suter, C. M., & Ward, R. L. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00633-0 · Cited by 84 · cited 1×
“CD103 is expressed at high levels by mucosal CD8 T lymphocytes, in particular intestinal intraepithelial lymphocytes (4), but it is also found on mucosal mast cells and dendritic cells (5), CD4 and CD8 regulatory T cells (6), and on a large proportion of CD8 T cells infiltrating epithelial tumors, including pancreatic…”
BackgroundαEβ7 (CD103) Expression Identifies a Highly Active, Tonsil-Resident Effector-Memory CTL Population
Woodberry, T., Suscovich, T. J., Henry, L. M., August, M. A., Waring, M. T., Kaur, A., Hess, C., Kutok, J. L., Aster, J. C., Wang, F., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4355 · Cited by 74
Webb, J. R., Wick, D. A., Nielsen, J. S., Tran, E., Milne, K., McMurtrie, E., & Nelson, B. H. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.016 · Cited by 70 · cited 2×
“CD103 is expressed at high levels by mucosal CD8 T lymphocytes, in particular intestinal intraepithelial lymphocytes (4), but it is also found on mucosal mast cells and dendritic cells (5), CD4 and CD8 regulatory T cells (6), and on a large proportion of CD8 T cells infiltrating epithelial tumors, including pancreatic…”
BackgroundTissue‐resident T cells, in situ immunity and transplantation
Turner, D., Gordon, C. L., & Färber, D. L. (2014) · Immunological Reviews · doi:10.1111/imr.12149 · Cited by 62
Tumour-immune cell interactions modulated by chemokines
Jöhrer, K., Pleyer, L., Olivier, A., Maizner, E., Zelle‐Rieser, C., & Greil, R. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.3.269 · Cited by 50 · cited 1×
“Indeed, intratumoral production of CCL5 and CCL3 was reported to promote recruitment of CD8 T cells and, thereby, CTL-dependent control of tumor progression (47).”
BackgroundUekusa, Y., Yu, W. G., Mukai, T., Gao, P. H., Yamaguchi, N., Murai, M., Matsushima, K., Obika, S., Imanishi, T., Higashibata, Y., et al. (2002) · PubMed · Cited by 47
T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy?
French, J., Cresswell, J., Wong, W. K., Seymour, K., Charnley, R., & Kirby, J. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600597 · Cited by 46
Zimmermann, T., Moehler, M. H., Gockel, I., Sgourakis, G. G., Biesterfeld, S., Müller, M., Berger, M. R., Lang, H., Galle, P. R., & Schimanski, C. C. (2010) · International Journal of Colorectal Disease · doi:10.1007/s00384-009-0868-y · Cited by 36 · cited 1×
“tration, poor prognosis (48, 49), and reduced efficacy of cancer immunotherapy (50).”
BackgroundGebhardt, T., & Carbone, F. (2009) · Nature · doi:10.1038/462418a · Cited by 8 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
Background
Cited by
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours
Milner, J. J., Toma, C., Yu, B., Zhang, K., Omilusik, K., Phan, A. T., Wang, D., Getzler, A. J., Nguyen, T., Crotty, S., et al. (2017) · Nature · doi:10.1038/nature24993 · Cited by 677
Metadata
- Authors
- Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F.
- Affiliations
- Université Paris-Sud (FR)
- INSERM Unité 1186 , 94805 Villejuif ,
- Institute Mutualiste Montsouris (FR)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 194
- Issue
- 7
- Pages
- 3475-3486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1895620535
- Cited by
- 622
- References
- 51
- Citations by year
- 2026: 34 · 2025: 61 · 2024: 51 · 2023: 55 · 2022: 63 · 2021: 81 · 2020: 72 · 2019: 70 · 2018: 66 · 2017: 27 · 2016: 28 · 2015: 13
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, tissue-resident memory T cells, non-small cell lung cancer, PD-1, TIM-3, immune checkpoint blockade, T cell exhaustion, intraepithelial lymphocytes, patient survival, prognostic factors, T cell cytotoxicity
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Female, Humans, Immunologic Memory, Lung Neoplasms, Lymphocyte Activation, Male, Membrane Proteins, Middle Aged, Neoplasm Staging, Organ Specificity, Prognosis, Risk Factors, Antigens, CD, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, Gene Expression Profiling, Integrin alpha Chains, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.